Production (Stage)
SAB Biotherapeutics, Inc.
SABS
$1.93
$0.126.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.40% | 50.15% | -102.84% | -6.61% | 31.66% |
| Total Depreciation and Amortization | -60.79% | -16.80% | -1.88% | 18.27% | 114.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.96% | -66.70% | 124.04% | -261.64% | -904.11% |
| Change in Net Operating Assets | 138.37% | -340.88% | 240.25% | 609.70% | -165.88% |
| Cash from Operations | 27.47% | 29.11% | -21.75% | -57.53% | -569.49% |
| Capital Expenditure | -- | 18.41% | -17.58% | -131.28% | -506.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 114.96% | -- | -- | -- | -- |
| Cash from Investing | 114.90% | 13,841.97% | -2,718.09% | 49,522.03% | -147,126.29% |
| Total Debt Issued | -- | -32.57% | -- | -- | -- |
| Total Debt Repaid | 30.52% | 4.63% | -354.87% | 30.65% | 31.60% |
| Issuance of Common Stock | -- | -- | -100.00% | -- | 973.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 55.88% | -99.68% | -380.47% | 11.76% | -9.62% |
| Foreign Exchange rate Adjustments | 250.18% | -1,695.03% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.34% | -100.50% | -50.89% | 160.70% | -2,040.72% |